Sugi Predict

Sugi Predict / Compounds / SCHEMBL948136

SCHEMBL948136

SCHEMBL948136

CC(C)(C)OC(=O)N1CCC(NCCO)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 1/20 0.57
▸ ALDH1A1 P00352 2/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ RECQL P46063 1/20 0.47
▸ PTPN2 P17706 1/20 0.46
▸ PTPN1 P18031 1/20 0.46
▸ PTPN6 P29350 1/20 0.46
▸ EPHX2 P34913 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.45
▸ PKM P14618 1/20 0.45
▸ USP2 O75604 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ GPR119 Q8TDV5 2/20 0.44
▸ NR1H2 P55055 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL477204 0.91 EPHX1 (0.55) EPHX1ALDH1A1L3MBTL1MAPTNPC1
SCHEMBL23555643 0.91 EPHX1 (0.51) EPHX1ALDH1A1L3MBTL1MAPTNPC1
SCHEMBL12501233 0.88 EPHX1 (0.57) EPHX1ALDH1A1L3MBTL1MAPTNPC1
SCHEMBL3315489 0.88 EPHX1 (0.57) EPHX1ALDH1A1L3MBTL1MAPTNPC1
SCHEMBL5996731 0.87 EPHX1 (0.56) EPHX1ALDH1A1L3MBTL1MAPTNPC1
SCHEMBL3249883 0.87 EPHX1 (0.56) EPHX1ALDH1A1L3MBTL1MAPTNPC1
SCHEMBL3571988 0.87 EPHX1 (0.59) EPHX1ALDH1A1L3MBTL1MAPTNPC1
SCHEMBL13844118 0.87 EPHX1 (0.56) EPHX1ALDH1A1L3MBTL1MAPTNPC1
SCHEMBL842180 0.85 EPHX1 (0.55) EPHX1ALDH1A1L3MBTL1MAPTNPC1
SCHEMBL12267865 0.85 EPHX1 (0.55) EPHX1ALDH1A1L3MBTL1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250268919-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AMNEAL PHARMACEUTICALS LLC 2025-08-28 — — US disclosed
EP-4444318-A1 COMPOUNDS FOR THE TREATMENT OF CANCER Kashiv Biosciences, LLC (US) 2024-10-16 — — EP disclosed
WO-2024054512-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-03-14 — — WO disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 — — US disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 — — US disclosed
WO-2023105303-A1 COMPOUNDS FOR THE TREATMENT OF CANCER KASHIV BIOSCIENCES, LLC (US) 2023-06-15 — — WO disclosed
WO-2023105303-A1 COMPOUNDS FOR THE TREATMENT OF CANCER KASHIV BIOSCIENCES, LLC (US) 2023-06-15 — — WO disclosed
EP-2699546-B1 GAS CAPTURE PROCESS COMMONWEALTH SCIENT & INDUSTRIAL RESEARCH ORGANISATION (AU) 2019-06-26 — — EP disclosed
EP-2699546-B1 GAS CAPTURE PROCESS COMMONWEALTH SCIENT & INDUSTRIAL RESEARCH ORGANISATION (AU) 2019-06-26 — — EP disclosed
US-9409122-B2 Gas capture process COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2016-08-09 — — US disclosed
US-7709511-B2 Benzothiazolone derivatives ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-7534887-B2 Thiazoline derivative and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-19 — — US disclosed
US-20080300275-A1 Novel Benzothiazolone Derivatives ASTRAZENECA AB (SE) 2008-12-04 — — US disclosed
US-20070093501-A1 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-26 — — US disclosed
US-20070010528-A1 Thiazoline derivative and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-11 — — US disclosed
US-20070004736-A1 Imidazole derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-04 — — US disclosed
EP-1695961-A1 UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2006-08-30 — — EP disclosed
EP-1669352-A1 THIAZOLINE DERIVATIVE AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2006-06-14 — — EP disclosed
EP-1564213-A1 IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-08-17 — — EP disclosed
US-5854268-A Azetidine, pyrrolidine and piperidine derivatives MERCK SHARP & DOHME, LTD. (GB) 1998-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010528-A1 Thiazoline derivative and use of the same TBXA2R, F2, F3 EPHX1 1093/4885ALDH1A1 2163/4885L3MBTL1 2811/4885
US-20070004736-A1 Imidazole derivative, process for producing the same, and use HRH4, F2, HRH2 EPHX1 789/4885ALDH1A1 2246/4885L3MBTL1 2949/4885
US-20250268919-A1 COMPOUNDS FOR THE TREATMENT OF CANCER BRCA1, KLK3, BRDT EPHX1 1697/4885ALDH1A1 244/4885L3MBTL1 4386/4885
US-20080300275-A1 Novel Benzothiazolone Derivatives NR0B1, RB1, CCND1 EPHX1 2748/4885ALDH1A1 233/4885L3MBTL1 1114/4885
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS SREBF1, SREBF2, NR1H3 EPHX1 842/4885ALDH1A1 3647/4885L3MBTL1 3281/4885
US-20070093501-A1 Urea derivative, process for producing the same, and use F2, URB2, F12 EPHX1 2064/4885ALDH1A1 3712/4885L3MBTL1 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.